Abstract
Background
The therapeutic outcome and toxicity of 3-D conformal photon external beam therapy of prostate cancer is well documented in the literature. Progress is still in work for optimization of treatment strategies by risk-adapted dose escalation studies to improve local tumor control without increase of radiation side effects.
Patients and Methods
We present our experience of 291 patients treated between January 1994 and August 1997 with a 3-D planned four-field box technique and a central dose of 66 Gy. Biochemical response of patients with radiotherapy alone (group 1, n=72 pts.) has been analyzed in detail. Acute radiation side effects are given for all patients (n=291), late radiation side effects are given for patients treated between Jan 1994 and Jan 1996 with a median follow-up of 22 months (n=115 pts.).
Results
We have observed a biochemical response (nadir PSA<1 after 12 months, <2 after 6 months) for patients treated with radiotherapy alone without hormone manipulation in 67%. Incidence of late rectal and bladder morbidity (grade 2 and 3) was 9.4% and 4%, respectively.
Conclusion
Compared to other reports our results indicate a high rate of local tumor control (early biochemical response) and a low rate of late morbidity. Nevertheless, we will start a risk-adapted dose escalation study up to 74 Gy for unfavorable subgroups (G2-3, Gleason Score>7, PSA>10) to improve treatment outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:311–17.
Hanks GE, Lee WR, Hanlon AL, et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml. Int J Radiat Oncol Biol Phys 1996;35:861–8.
Hanks GE, Schultheiss TE, Hanlon AL, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37:543–50.
Hanks GE, Schultheiss TE, Hunt MA, et al. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995;31:25–9.
Kavadi VS, Zagars GK, Pollack A. Serum prostatic-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994;30:279–87.
Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3–11.
Soffen EM, Hanks GE, Hunt MA, et al. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992;24:485–8.
Tait DM, Nahum AE, Meyer LC, et al. Acute toxicity in pelvic radiotherapy: a randomised trial of conformal versus conventional treatment. Radiother Oncol 1997;42:121–36.
Wachter S, Gerstner N, Dieckmann K, et al. Factors predicting for late rectal morbidity after 3-d-planned radiotherapy of localized prostate cancer. Radiother Oncol 1996;40(suppl. 1):184
Wachter S, Gerstner N, Dieckmann K, et al. Dreidimensional geplante kleinvolumige Konformationsbestrahlung des lokalen Prostatakarzinoms. Strahlenther Onkol 1997;5:253–60.
Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786–91.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wachter, S., Gerstner, N., Goldner, G. et al. Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: Early results. Strahlenther Onkol 175 (Suppl 2), 84–86 (1999). https://doi.org/10.1007/BF03038898
Issue Date:
DOI: https://doi.org/10.1007/BF03038898